New Drug Curbs Breast Cancer
After Standard Therapy Ends

Post-menopausal women with breast cancer who took the drug Femara after standard therapy had a 40% reduction in the rate of cancer recurrence in other parts of the body, researchers said.

The study of 5,200 women, presented at the American Society of Clinical Oncology meeting in New Orleans, also found that the drug boosted the survival rate after two and a half years among women whose cancer already had spread to their lymph nodes at the time of diagnosis. Femara is made by Swiss drug maker Novartis AG, which financed the...